Medicina
Departamento
University of Paris-Saclay
Gif-sur-Yvette, FranciaPublicaciones en colaboración con investigadoras/es de University of Paris-Saclay (7)
2024
-
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259
2022
-
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Journal of Clinical Medicine, Vol. 11, Núm. 6
2021
-
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 4, pp. 463-475
-
European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance
Annals of the Rheumatic Diseases, Vol. 80, Núm. 6, pp. 775-781
2020
-
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities
Annals of the Rheumatic Diseases, Vol. 79, Núm. 10, pp. 1333-1339
2019
-
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1151-1159
2016
-
Off-label use of rituximab for systemic lupus erythematosus in Europe
Lupus Science and Medicine, Vol. 3, Núm. 1